Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract

Cancer Science

Volumn 103, Issue 3, 2012, Pages 593-599

  Fijneman, Remond J A ^a   Anderson, Rebecca A ^b   Richards, Ethan ^b   Liu, Jieming ^b   Tijssen, Marianne ^a   Meijer, Gerrit A ^a   Anderson, Janae ^b   Rod, Annette ^b   O'Sullivan, Michael G ^c   Scott, Patricia M ^b   Cormier, Robert T ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1; RUNX1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; COLON MUCOSA; COLON TUMOR; CONTROLLED STUDY; DUODENUM TUMOR; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENOME ANALYSIS; INFLAMMATION; INTESTINE EPITHELIUM CELL; METABOLISM; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX1 GENE; STEM CELL EXPANSION; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; C57BL MOUSE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; INTESTINE MUCOSA; MALE; MOUSE MUTANT; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL;

ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS;

EID: 84859705566     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02189.x     Document Type: Article

References (86)

1. Coffman JA. Is Runx a linchpin for developmental signaling in metazoans? J Cell Biochem 2009 107: 194-202.
2. Cohen MM Jr; Perspectives on RUNX genes: an update. Am J Med Genet 2009; 149A: 2629-46.
3. Taniuchi I, Osato M, Egawa T et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002; 111: 621-33.
4. Yamada R, Ymamoto K. Recent findings on genes associated with inflammatory disease. Mutat Res 2005; 573: 136-51.
5. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-87.
6. Niebuhr B, Fischer M, Tager M, Cammenga J, Stocking C. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis 2008; 40: 211-8.
7. Cheng CK, Li L, Cheng SH et al. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia. Blood 2011; 118: 6638-48.
8. ter Elst A, Ma B, Scherpen FJG et al. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 2011; 71(7): 2761-71.
9. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502-13.
10. Kundu M, Compton S, Garrett-Beal L et al. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma. Blood 2005; 106: 3621-4.
11. Beri-Dexheimer M, Latger-Cannard V, Philippe C et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 2008; 16: 1014-8.
12. Owen CJ, Toze CL, Koochin A et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008; 112: 4639-45.
13. Preudhomme C, Renneville A, Bourdon V et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009; 113: 5583-7.
14. Kuo MC, Liang DC, Huang CF et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009; 23: 1426-31.
15. Schegelberger B, Gohring G, Thol F, Heuser M. Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leuk Lymphoma 2011; DOI: 10.3109/10428194.2011.618235 [Epub ahead of print].
16. Hoi CS, Lee SE, Lu SY et al. Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. Mol Cell Biol 2010; 30: 2518-36.
17. Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol Cancer Res 2008.
18. Birnbaum DJ, Adelaide J, Mamessier E et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosom Cancer 2011; 50: 456-65.
19. Boonstra JJ, van Marion R, Douben HJCW et al. Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts. Genes Chromosom Cancer 2011; DOI: 10.1002/gcc.20952 [Epub ahead of print].
20. Janes KA. RUNX1 and its understudied role in breast cancer. Cell Cycle 2011; 10(20): 3461-5.
21. Wang L, Brugge JS, Janes KA. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 2011; 108: E803-12.
22. Sakakura C, Hagiwara A, Miyagawa K et al. Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int J Cancer 2005; 113: 221-8.
23. March HN, Rust AG, Wright NA et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 2011; 43: 1202-9.
24. Chen W, Gao N, Shen Y, Cen JN. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 2010; 25: 823-31.
25. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-15.
26. Ito K, Inoue KI, Bae SC, Ito Y. Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 2009; 28: 1379-84.
27. Lee CW, Ito K, Ito Y. Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer. Cancer Res 2010; 70: 4243-52.
28. Shiraha H, Nishina S, Yamamoto K. Loss of Runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem 2011; 112: 745-9.
29. Lim B, Ju H, Kim M, Kang C. Increased genetic susceptibility to intestinaltype gastric cancer is associated with increased activity of the RUNX3 distal promoter. Cancer 2011; 117: 5161-71.
30. Hu SL, Kong XY, Cheng ZD et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 2010; 96: 726-33.
31. Brenner O, Levanon D, Negreanu V et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA 2004; 101: 16016-21.
32. Sugai M, Aoki K, Osato M et al. Runx3 is required for full activation of regulatory T cells to prevent colitis-associated tumor formation. J Immunol 2011; 186: 6515-20.
33. Garrity-Park M, Loftus EV, Sandborn WJ, Smyrk T. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis 2011; DOI: 10.1002/ibd.21681 [Epub ahead of print].
34. Watanabe T, Kobunai T, Ikeuchi H et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol 2011; 38: 201-7.
35. Ibrahim AE, Arends MJ, Silva AL et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 2011; 60: 499-508.
36. Nishio M, Sakakura C, Nagata T et al. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability as a novel serum marker. Anticancer Res 2010; 30: 2673-82.
37. Kodach LL, Jacobs RJ, Heijmans J et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010; 31: 1567-75.
38. Slattery ML, Lundgreen A, Herrick JS et al. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-b-signaling pathway. Carcinogenesis 2011; 32: 318-26.
39. Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Caan BJ. Genetic variation in the transforming growth factor-beta signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer 2011; 117: 4175-83.
40. Blyth K, Vaillant F, Jenkins A et al. Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis 2010; 45: 117-23.
41. Buchert M, Darido C, Lagerqvist E et al. The symplekin/ZONAB complex inhibits intestinal cell differentiation by the repression of AML1/Runx1. Gastroenterology 2009; 137: 156-64.
42. Burns CE, Traver D, Mayhall E, Shepard JL, Zon LI. Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev 2005; 19: 2331-42.
43. Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARPmediated repression of notch target genes. Mol Cell Biol 2008; 28: 3502-12.
44. Nakagawa M, Ichikawa M, Kumano K et al. AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. Blood 2006; 108: 3329-34.
45. van Es JH, van Gijn ME, Riccio O et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959-63.
46. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006; 7: 349-59.
47. Sikandar SS, Pate KT, Anderson S et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010; 70: 1469-78.
48. Chu D, Li Y, Wang W et al. High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 2010; 17: 1337-42.
49. Zheng H, Pritchard DM, Yang X et al. KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol 2009; 296: G490-8.
50. McAlpine CA, Barak Y, Matise I, Cormier RT. Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer 2006; 119: 2339-46.
51. Cormier RT, Hong KH, Halberg RB et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997; 17: 88-91.
52. Fijneman RJ, Bade LK, Peham JR et al. Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Cell Oncol 2009; 31: 345-56.
53. Mootha VK, Lindgren CM, Eriksson KF et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-73.
54. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
55. Battistelli S, Stefanoni M, Lorenzi B et al. Coagulation factor levels in nonmetastatic colorectal cancer patients. Int J Biol Markers 2008; 23: 36-41.
56. Ross ME, Mahfouz R, Onciu M et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679-87.
57. Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009; 15: 1391-6.
58. Kanehisa M, Araki M, Goto S et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: D480-4.
59. Boquest AC, Shahdadfar A, Fronsdal K et al. Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell 2005; 16: 1131-41.
60. Bruno L, Hoffmann R, McBlane F et al. Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro. Mol Cell Biol 2004; 24: 741-56.
61. Jechlinger M, Grunert S, Tamir IH et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003; 22: 7155-69.
62. Van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
63. Tomita H, Yamada Y, Oyama T et al. Development of gastric tumors in ApcMin/+ mice by the activation of the b-Catenin/Tcf signaling pathway. Cancer Res 2007; 67: 4079-87.
64. Qiao X, Ziel JW, McKimpson W et al. Prospective identification of a multilineage progenitor in murine stomach epithelium. Gastroenterology 2007; 133: 1989-98.
65. Li Q, Wang L, Jia Z, Wei D, Le X, Xie K. Conditional inactivation of Klf4 gene in distinct cell population of stomach mucosa renders mice susceptible to gastric carcinogenesis. Published Abstract # 0954, International Society of Gastrointestinal Oncology, 2009 Gastrointestinal Oncology Conference, 1-3 October 2009.
66. Hoek RM, de Launay D, Kop EN et al. Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum 2010; 62: 1036-42.
67. Blom AM, Villoutreix BO, Dahlback B. Functions of human complement inhibitor C4b-binding protein in relation to its structure. Arch Immunol Ther Exp 2004; 52: 83-95.
68. Kim DD, Song WC. Membrane complement regulatory proteins. J Clin Immunol 2006; 118: 127-36.
69. Holla VR, Wang D, Brown JR, Mann JR, Katkuri S, DuBois RN. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem 2005; 280: 476-83.
70. Mikesch JH, Buerger H, Simon R, Brandt B. Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta 2006; 1766: 42-52.
71. Han SL, Xu C, Wu XL, Li JL, Liu Z, Zeng QQ. The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis 2010; 25: 695-702.
72. Herbert DR, Yang JQ, Hogan SP et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med 2009; 206: 2947-57.
73. Nair MG, Guild KJ, Du Y et al. Goblet cell-derived resistin-like molecule beta augments CD4 + T cell production of IFN-gamma and infection-induced intestinal inflammation. J Immunol 2008; 181: 4709-15.
74. Zheng LD, Tong QS, Weng MX et al. Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci 2009; 54: 274-81.
75. Leclerc D, Deng L, Trasler J, Rozen R. ApcMin/+ mouse model of colon cancer: gene expression profiling in tumors. J Cell Biochem 2004; 93: 1242-54.
76. Andreu P, Peignon G, Slomianny C et al. A genetic study of the role of the Wnt/beta-catenin signalling in Paneth cell differentiation. Dev Biol 2008; 324: 288-96.
77. Gregorieff A, Stange DE, Kujala P et al. The ets-domain transcription factor Spdef promotes maturation of goblet and paneth cells in the intestinal epithelium. Gastroenterology 2009; 137: 1333-45.
78. Flandez M, Guilmeau S, Blache P, Augenlicht LH. KLF4 regulation in intestinal epithelial cell maturation. Exp Cell Res 2008; 314: 3712-23.
79. Ghaleb AM, McConnell BB, Kaestner KH, Yang VW. Altered intestinal epithelial homeostasis in mice with intestine-specific deletion of the Krüppellike factor 4 gene. Dev Biol 2011; 349: 310-20.
80. Ghaleb AM, McConnell BB, Nandan MO, Katz JP, Kaestner KH, Yang VW. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res 2007; 67: 7147-54.
81. Wei D, Kanai M, Huang S, Xie K. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 2006; 27: 23-31.
82. Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 2001; 294: 2155-8.
83. Gao J, Chen Y, Wu KC et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 2010; 316: 149-57.
84. Nishina SI, Shiraha H, Nakanishi Y et al. Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol Rep 2011; 26: 523-31.
85. Wang CQ, Jacob B, Nah GS, Osato M. Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis 2010; 44: 275-86.
86. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-9.